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CONCLUSIONS: At present, there are 1469 medicines on the Slovak market includ-
ing atorvastatin, while there are only 244 with simvastatin and 6 with lovastatin as
active ingredient. The decrease in use of simavstatin might be also caused by
appearance of its associated side-effects including myopathy. Rosuvastatin pres-
ents good alternative of treatment when the effectiveness of classic statins is not
sufficient.
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OBJECTIVES: Act No. 140/1998 on Drugs and Medicinal Aids which is valid in Slo-
vakia to the november 2011, possible to apply non-compulsory generic substitution
in community pharmacies. However, according to available data, applied only in 5
to 10 percent. New Act on Drugs and Medicinal Aids (Act No. 362/2011) entered into
force from 1. december 2011, which introduced required generic prescription to
ensure adequate health care for the insured, to improve health and enhance the
quality and availability of health care in the effective use of funds. The aim is to
reduce the ever rising cost of health care. The cardiovascular disease is making the
largest share of financial costs.METHODS:Drugs expenditure derived from data of
the General Health Insurance. RESULTS: In Slovakia during the period 2009-2011
constituted the largest average share of total spending on medicines covered by the
public health insurance ATC group C, 22.7% (cardiovascular system). Despite a
decline in drug packages issued for cardiovascular disease in the last year of 3.25%,
there has been an increase in the value of the funds of 3.14% of public health
insurance. Research focused on share and impact of generic substitution made in
the Slovak pharmacies in 2010-2011 showed the most substituted products in ATC
group C (36.14%), with the most substituted drugs belong amlodipine (6.26%) and
atorvastatin (4.97%).CONCLUSIONS: In recent years, increasing the volume of pub-
lic expenditure on drugs co-payment patient is growing rapidly. The use of generic
drugs is to reduce consumption and costs for medication, not to the detriment
quality therapy. One of the aims of the new law about medicines and medical
devices to bring savings to the state and citizens in the area of drugs. Preliminary
studies suggest differences.
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OBJECTIVES: The burden of chronic diseases is an important parameter for finan-
cial resource allocation and health care system capacity planning. Future preva-
lence and distribution of chronic conditions depend on the development of popu-
lation size and structure. The European population is expected to slowly grow and
rapidly age in the next decades. Our contribution aims at evaluating the impact of
demographic change on prevalence of hypertension in Europe. The use of projec-
tions to support long-term planning of health care resources will be discussed.
METHODS: A prevalence-projection scenario was developed combining age-/sex-
specific population projections with chronic disease prevalence rates. Population
projections were taken from Eurostat statistics. Hypertension prevalence rates
were estimated from the European Healthcare Access Panel (EHP, 2008), a repre-
sentative health and health care utilization survey in five EU countries (Germany,
UK, France, Italy and Spain). The weighted sample comprised 136.397 respondents
aged 20-79. Multiplying projected population numbers with the respective age- and
sex-specific hypertension rates from 2008 provided an estimate for the number of
hypertensives by country in forthcoming years. RESULTS: As calculated from EHP
data, in 2010, 15.9M Germans aged 20 to 79 years suffered from hypertension (10.4M
in UK, 8.2M in France, 9.7M in Italy and 6.4M in Spain). For the year 2025, our model
predicts the prevalence figures to increase to 17.3M in Germany, 12.3M in UK, 9.6M
in France, 11.3M in Italy and 7.8M in Spain. For all five countries combined hyper-
tension is calculated to increase by 15.3%, from 50.6M to 58.4M. CONCLUSIONS:
The projections show a considerable increase in the prevalence of hypertension:
the total population in the five biggest EU countries will grow only by 5.7% but the
number of people with hypertension will increase by 15.3%. These data quantify
the influence of ageing on disease burden and reflect an increased need for appro-
priate health care expenditure and capacities.
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OBJECTIVES:The impact of the type of drug insurance plan on costs of medications
is not well known. We aimed to compare the costs of antidepressants and statins,
two of the most prescribed drugs, in Québec patients who are covered by private
and public drug insurance. METHODS: Two matched cohort studies were con-
ducted using prescription claims databases for Quebec residents with private
(reMed) and public drug insurance (RAMQ). Patients were aged 18 to 64 years and
filled at least one prescription for an antidepressant (Cohort 1) or a statin (Cohort 2)
in monotherapy between December 2007 and September 2009. The average
monthly costs (medication cost  dispensing fee) of antidepressants and statins
per patient and the percent cost difference for a 30-day prescription for each anti-
depressant and each statin product were compared between patients with private
and public drug insurance using t-tests and regressionn models. RESULTS: Cohort
1 included 194 privately and 1923 publicly insured patients while the correspond-
ing figures for Cohort 2 were 174 and 1712, respectively. The average cost of anti-
depressants and statins per patient per month was significantly higher among
privately-insured than publicly-insured patients [Cohort 1: $48.1725.19 vs.
$33.7217.58, p0.001; Cohort 2: $61.1922.31 vs. $54.6220.48$, p0.001]. The
cost of 30-day prescriptions for most individual drugs of antidepressants and st-
atins was significantly more expensive for privately-insured patients than
publicly-insured patients. CONCLUSIONS: Higher cost of antidepressants and st-
atins observed in privately-insured patients might be due to different pharmacy
payment requirements and the dispensing fee restrictions under the public plan.
More research is need to investigate whehter or not this higer drug cost translates
into lower patient’s adherence and persistence to medications.
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OBJECTIVES: To assess the effectiveness of an educational patient-centered pro-
gram on the reduction of Blood Pressure (BP) by a better adherence to pharmaco-
logical and non pharmacological treatment. METHODS: A randomized controlled
study including hypertensive patients (SBP135 mmHg and DBP85 mmHg) 18
years of age or older. Patients were enrolled by the Center for the Diagnosis and
Treatment of Hypertension Cardarelli Hospital and were randomly assigned to
Control group (C) and Intervention group (I ). Group I, in addition to the routine care,
received a Patient Information Leaflet giving information on hypertension and
participated to three educational group sessions (designed according to the focus
group and role playing methods), respectively at 2,4 and 9 months after the recruit-
ment. Group C received the routine care. Both groups received a control visit with
BP measure at 2, 4 and 9 months after the recruitment. The primary outcome was
the change in BP values. BP measurements were assessed according to the inter-
national guidelines. Information on patients’ demographics, co-morbidity and
drugs were collected at baseline and at 12-month-follow-up. RESULTS: A total of
627 patients were randomly assigned to the study (418 in the Group C and 209 in the
Group I). There were no significant differences (P0.05) in both groups concerning
age and gender. A greater reduction of SBP was observed in the Group I (-6.0 mmHg
14.0 vs -3.4 mmHg 11.3, P0.05 ) CONCLUSIONS: Educational patient-centered
program may be an effective strategy to improve blood pressure control, due a
better adherence to therapy and a more careful health behavior.
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OBJECTIVES: To investigate the extent to which the convenience offered by fixed-
dose combination preparations is valued by payers when performing Health Tech-
nology Assessments (HTA). METHODS: Publication lists of major European HTA
agencies (SMC, HAS, IQWiG, NICE, UVEF, AHTAPoL, TLV, CVZ) were searched man-
ually for appraisals on fixed-dose combination drugs from 2010 onwards. Of the
agencies that published assessments, the payers’ perception of fixed-dose combi-
nation regarding their potential of improving adherence was evaluated. The inves-
tigation focused on three large therapeutic areas: diabetes, hypertension, rheuma-
toid arthritis. RESULTS: We identified 135 assessments of diabetes (61),
hypertension (36), and rheumatoid arthritis (38) medications. 11 HTAs assessed
fixed-dose combination preparations. Of these, 9 HTAs, conducted by two agencies
(SMC and HAS), provided insights on adherence and ease of use. While SMC in
general recognizes the potential advantage of fixed-dose combination to reduce a
patient’s pill burden at no additional or moderately higher costs, clinical trials did
not provide any proof. Issues seen were differences in recommended dosing levels
between the normal formulations and the fixed-dose preparations, exhibiting po-
tential safety risks to be weighed against potential benefits. Likewise, HAS could
not find a benefit of fixed-dose over free dose combinations in terms of efficacy and
quality of life. In addition, HAS holds the opinion that dose combinations of more
than two drugs strongly limit individual up-titration, and may lead to over-pre-
scribing and misuse, thereby making the medical benefit insufficient for
reimbursement.CONCLUSIONS:Adherence is inversely related to the number of doses
per day, and poor adherence is the primary reason for sub-optimal clinical benefit, re-
duces patient’s quality of life and wastes health-resources. Although fixed-dose combi-
nation preparations can significantly increase patient adherence, our analysis showed
that HTA agencies would only recognize the value of fixed-dose combinations for reim-
bursement decisions if clinical proof of superior adherence was available.
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OBJECTIVES:Analyses were conducted on Republic of Srpska (RS) Health Insurance
Fund (HIF) national prescription database. Analyses explored health expenditure
differences in pharmaceutical consumption for the fiscal year 2011 versus 2010. RS
HIF provides coverage for a population of 1.2 million. METHODS: RS HIF national
prescription database was explored to determine expenditure breakdown by ther-
apeutic category and the appropriate positive list designation. Key cost drivers and
the differences between two fiscal years in each therapeutic category were identi-
fied. Positive lists A (drugs at reimbursement rate of 90%), A1 (drugs not registered
with Agency for Drug Approval required to treat certain conditions at reimburse-
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